Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-aventis Acquires Antisoma's Leukemia Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi-aventis Acquires Antisoma’s Leukemia Drug

Sanofi-aventis U.S. has acquired commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug, from biotechnology company Antisoma.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-aventis U.S. has acquired commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug, from biotechnology company Antisoma. Oforta is currently approved in the U.S. for use as a second-line therapy to treat adults with B-cell CLL.

“We are extremely pleased to add Oforta to our existing oncology portfolio, and believe it represents an exciting opportunity for Sanofi-aventis U.S.,” said John Harrington, vice president and head of the Oncology Business Unit at sanofi-aventis U.S. “Sanofi-aventis is a company committed to identifying and exploring new treatment options for patients facing serious diseases, such as CLL. This agreement further supports our efforts to help patients and complements our strong heritage of providing therapies to treat cancer.”

Antisoma currently licenses certain rights and purchases Oforta from Bayer Schering Pharma AG. As part of this transaction, Sanofi-aventis U.S. will also acquire these agreements.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters